Which Patients Benefit Most from HER2 Therapy?
HER2 therapy refers to a group of targeted cancer treatments that interfere with the HER2 (human epidermal growth factor receptor 2) protein or gene alterations that drive tumor growth. Over the last two decades, anti-HER2 medicines—from monoclonal antibodies to small molecules and antibody‑drug conjugates (ADCs)—have changed outcomes for people with HER2-driven cancers. Understanding which patients benefit most requires clear knowledge of how HER2 is measured, the differences between HER2‑positive and HER2‑low disease, and the specific safety and effectiveness profiles of available therapies.
How HER2 status is defined and why it matters
HER2 status is routinely determined on tumor tissue using immunohistochemistry (IHC) to measure protein expression and in situ hybridization (ISH/FISH) to detect gene amplification. Traditionally, tumors with strong HER2 overexpression (IHC 3+) or with HER2 gene amplification by ISH are labeled HER2‑positive and have been the primary group to receive anti‑HER2 drugs such as trastuzumab and pertuzumab. More recently, the concept of HER2‑low (IHC 1+ or IHC 2+/ISH‑) emerged because certain ADCs have shown activity in that group. Professional bodies (ASCO and the College of American Pathologists) have reaffirmed existing testing standards while advising pathologists and clinicians to be aware that distinctions such as IHC 0 vs 1+ may affect treatment options in the metastatic setting.
Key components of HER2 therapy and patient selection
HER2‑targeted options fall into several classes: monoclonal antibodies (e.g., trastuzumab, pertuzumab), tyrosine kinase inhibitors (e.g., lapatinib, tucatinib), and antibody‑drug conjugates (e.g., trastuzumab emtansine [T‑DM1], trastuzumab deruxtecan/T‑DXd). Selection depends on cancer type, line of therapy, prior treatments, and precise HER2 testing results. For breast cancer, patients with IHC 3+ or ISH+ are candidates for established HER2 regimens in both early‑stage and metastatic settings; patients with HER2‑low metastatic breast cancer may now be candidates for specific ADCs shown to improve progression‑free and overall survival compared with standard chemotherapy in the later‑line setting. Outside breast cancer, HER2 overexpression or amplification can guide therapy in cancers such as gastric/gastroesophageal junction and, in some cases, inform investigational or tumor‑agnostic approaches for other HER2‑driven solid tumors.
Benefits and important considerations for patients
The most clear-cut benefits are observed in cancers with HER2 overexpression or amplification: improved tumor response rates, longer progression‑free survival, and, in many trials, improved overall survival when anti‑HER2 agents are added to chemotherapy or used in combination regimens. For patients with HER2‑low metastatic breast cancer, newer ADCs have produced clinically meaningful gains versus chemotherapy in randomized trials, expanding options for a previously underserved group. Important considerations include treatment‑related toxicities (for example, trastuzumab carries a risk of left ventricular dysfunction and ADCs such as trastuzumab deruxtecan carry a risk of interstitial lung disease/pneumonitis), prior treatment history, cardiac function, organ function, and patient goals of care. Shared decision‑making with an oncologist and the care team is essential.
Recent trends and innovations shaping who benefits
Recent clinical advances have broadened eligibility for HER2‑directed therapy. Antibody‑drug conjugates that deliver potent cytotoxics selectively to HER2‑expressing cells have been pivotal; some ADCs are effective in HER2‑low disease and have led to expanded regulatory approvals and changes in practice. Regulators have also issued tumor‑agnostic or broader accelerated approvals for certain HER2‑targeted agents in previously treated HER2‑positive solid tumors, reflecting a trend toward biomarker‑driven treatment regardless of the tissue of origin. At the same time, guideline panels have been cautious about designating new HER2 reporting categories and emphasize consistent, high‑quality HER2 testing to identify patients who truly benefit from specific agents.
Practical tips for patients and clinicians
1) Ensure accurate HER2 testing: confirm HER2 status on a recent and well‑handled tissue sample using validated IHC and ISH assays and discuss re‑testing if clinical circumstances change. 2) Review prior therapy: previous exposure to HER2‑directed agents affects later choices; some drugs are approved specifically after prior lines of therapy. 3) Assess baseline heart and lung status: document left ventricular ejection fraction before starting trastuzumab or combinations with known cardiac risk, and educate patients about respiratory symptoms that might signal pneumonitis with ADCs. 4) Consider clinical trials: for unusual HER2 alterations (mutations, focal amplification) or rare tumor types, trials may offer access to targeted agents. 5) Multidisciplinary care: involve medical oncology, pathology, cardiology (as needed), and, for surgical or radiation decisions, the appropriate specialists to individualize the plan.
Who benefits most: short profiles
Patients most likely to benefit fall into a few profiles: those with HER2‑positive breast cancer (IHC 3+ or gene amplification) across early and metastatic stages who receive established HER2 antibody and kinase inhibitor regimens; patients with HER2‑low metastatic breast cancer whose disease has progressed after prior lines of therapy and who may benefit from certain ADCs; and patients with HER2‑amplified gastric or gastroesophageal junction adenocarcinoma who can benefit from trastuzumab added to chemotherapy. For other tumor types with HER2 gene alterations (for example, select lung, colorectal, or other solid tumors), benefit depends on the alteration type and drug mechanism; genomic profiling and specialist input are vital.
Conclusion and practical takeaway
HER2 therapy is no longer a single‑disease, single‑drug concept: test accuracy, the biology of HER2 expression or alteration, and newer agents—particularly antibody‑drug conjugates—determine who benefits. Patients with clear HER2 overexpression or amplification have the strongest and most established benefit, while HER2‑low disease is an important, newer category for select metastatic breast cancer patients because of recent ADC data. Decisions should be individualized, based on validated testing, prior treatments, organ function, and the patient’s treatment goals. Discuss options with a multidisciplinary oncology team to align therapy choice and monitoring with the best available evidence.
| Patient group | Common HER2 test result | Typical HER2 therapy options | Key safety notes |
|---|---|---|---|
| HER2‑positive breast cancer | IHC 3+ or ISH/FISH positive | Trastuzumab ± pertuzumab, T‑DM1, tucatinib combinations, ADCs (as indicated) | Monitor LVEF; infusion reactions; manage cytopenias |
| HER2‑low metastatic breast cancer | IHC 1+ or IHC 2+/ISH‑ | Selected ADCs shown to improve PFS/OS after prior therapy | Risk of interstitial lung disease/pneumonitis; careful pulmonary monitoring |
| HER2‑amplified gastric/GEJ adenocarcinoma | IHC 3+ or ISH+ (per local guidelines) | Trastuzumab added to chemotherapy (first‑line) | Monitor cardiac function; standard chemotherapy toxicities |
| Other HER2‑altered solid tumors | Amplification or activating mutation (testing by NGS/IHC/ISH) | Off‑label or trial use of HER2‑targeted agents; some ADCs with tumor‑agnostic approvals | Benefit varies by alteration type; trial enrollment often recommended |
Frequently asked questions
- Q: What is the difference between HER2‑positive and HER2‑low? A: HER2‑positive refers to strong protein overexpression (IHC 3+) or gene amplification by ISH; HER2‑low describes tumors with low protein expression (IHC 1+ or IHC 2+/ISH‑) and may be eligible for specific ADCs in the metastatic setting.
- Q: Do all patients with HER2‑low breast cancer benefit from ADCs? A: Clinical trials have shown benefit in many patients with HER2‑low metastatic breast cancer, but eligibility and benefit depend on prior treatments, overall health, and exact test results; discuss specifics with your oncologist.
- Q: Can HER2 testing change over time? A: Yes—HER2 expression can differ between the primary tumor and metastases or change after treatment; if treatment decisions hinge on HER2 status, retesting may be appropriate.
- Q: What are the most serious side effects to watch for? A: Cardiac dysfunction (with some monoclonal antibodies) and interstitial lung disease/pneumonitis (reported with some ADCs) are among the most important; report new shortness of breath, cough, chest pain, or edema promptly.
Sources
- U.S. Food & Drug Administration — Approval information for trastuzumab deruxtecan (Enhertu) in HER2‑low breast cancer
- U.S. Food & Drug Administration — Accelerated approval summary for trastuzumab deruxtecan in HER2‑positive solid tumors
- DESTINY‑Breast04 trial (New England Journal of Medicine summary) — trastuzumab deruxtecan in HER2‑low advanced breast cancer
- ToGA trial (Lancet) — trastuzumab in HER2‑positive gastric/gastroesophageal junction cancer
- College of American Pathologists / ASCO — HER2 testing guidance and reaffirmation (2023)
Medical disclaimer: This article is for informational purposes only and does not replace individualized medical advice. For treatment decisions, testing interpretation, or symptom concerns, consult your treating oncologist or the appropriate specialist. If you are in the United States and have urgent symptoms such as new severe shortness of breath or fainting, seek emergency care immediately.
This text was generated using a large language model, and select text has been reviewed and moderated for purposes such as readability.
